Classification of Primary Angle Closure Disease by Hierarchical Cluster Analysis of Ocular Biometrics in the Dark and Light - Cho, Austin; Lewinger, Juan Pablo; Pardeshi, Anmol A.; Aroca, Galo Apolo; Torres, Mina; Nongpiur, Monisha; Jiang, Xuejuan; McKean-Cowdin, Roberta; Varma, Rohit; Xu, Benjamin Y. (medRxiv, 2023)
Purpose To investigate the classification of eyes with primary angle closure disease (PACD) based on hierarchical cluster analysis of ocular biometrics measured in the dark and light using anterior segment OCT (AS-OCT).Methods Participants of the Chinese American Study received complete eye exams, including gonioscopy and AS-OCT imaging, to identify primary angle closure suspects (PACS) and primary angle closure without/with glaucoma (PAC/G). Biometric parameters analyzed included angle opening distance (AOD750) and trabecular iris space area (TISA750), iris area (IA), iris thickness (IT750), iris curvature (IC), lens vault (LV), anterior chamber width (ACW) and anterior chamber depth (ACD). Hierarchical cluster analysis was performed using Ward’s method and Euclidean distance.Results Analysis of 159 eyes with PACS or PAC/G produced 2 clusters in both dark and light. In both analyses, the primary cluster (N=132 in the dark, N=126 in the light) was characterized by smaller AOD750 and TISA750, greater IC, and greater LV (p<0.001). The proportion of PACS to PAC/PACG eyes was significantly different between clusters in the light (p=0.02) but not the dark cluster analysis (p=0.08). On multivariable logistic regression analysis, smaller TISA750 (OR=0.84 per 0.01μm2) and AOD750 (OR=0.93 per 0.01mm) in the light and smaller TISA750 (OR=0.86 per 0.01μm2) in the dark were significantly associated (p≤ 0.02) with higher odds of PAC/G.Conclusion Cluster analysis of ocular biometrics can classify PACD eyes by disease severity. Ocular biometrics appear equally if not more strongly predictive of disease severity when measured in the light than dark. Clustering of biometric measurements obtained in the light could provide a novel method to risk-stratify patients for more severe PACD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants EY-017337 and K23 EY029763 from the National Eye Institute, National Institutes of Health, Bethesda, Maryland; and an unrestricted grant to the Department of Ophthalmology from Research to Prevent Blindness, New York, NY. S.Z. was supported by the Deans Research Scholars Program of the Keck School of Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Chinese American Study (CHES) was approved by the Ethics Committee from the University of Southern California Medical Center Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.